Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
2 new malaria treatments announced as drug resistance grows- Must-See Attractions in Australia
- Spots To Go Birdwatching All over the Planet
- Which Instax Camera Would it be a good idea for you to Purchase?
- Popular Home Rug Series For You
- January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
- Inn The executives: A Remunerating Profession Decision for Energetic People
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- 'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
